4//SEC Filing
Sullivan Timothy Eugene 4
Accession 0001492422-25-000011
CIK 0001492422other
Filed
Oct 22, 8:00 PM ET
Accepted
Oct 23, 4:20 PM ET
Size
9.4 KB
Accession
0001492422-25-000011
Insider Transaction Report
Form 4
Sullivan Timothy Eugene
Chief Financial Officer
Transactions
- Sale
Common Stock
2025-10-21$28.03/sh−10,000$280,300→ 110,936 total - Exercise/Conversion
Common Stock
2025-10-21$10.03/sh+10,000$100,300→ 120,936 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-10-21−10,000→ 232,903 totalExercise: $10.03Exp: 2027-10-18→ Common Stock (10,000 underlying)
Holdings
- 60,396(indirect: By Trust)
Common Stock
Footnotes (3)
- [F1]This is a scheduled exercise & sale from 10b5-1 trading plan dated June 9, 2025.
- [F2]The securities are held by The Timothy E Sullivan Irrevocable Trust of 2023. Patrick O. Collins is the trustee of The Timothy E Sullivan Irrevocable Trust of 2023. The reporting person disclaims beneficial ownership over the shares held by The Timothy E Sullivan Irrevocable Trust of 2023 except to the extent of his pecuniary interest therein.
- [F3]This option was granted on October 18, 2017 and fully vested.
Documents
Issuer
Apellis Pharmaceuticals, Inc.
CIK 0001492422
Entity typeother
Related Parties
1- filerCIK 0001707000
Filing Metadata
- Form type
- 4
- Filed
- Oct 22, 8:00 PM ET
- Accepted
- Oct 23, 4:20 PM ET
- Size
- 9.4 KB